Aurobindo Pharma Q1 Net Profit Rises 25% to Rs.1,032-Cr

Hyderabad, Aug. 5 (TNT): Aurobindo Pharma Ltd on Wednesday reported a 25.2 per cent year-on-year increase in consolidated net profit at ₹1,032 crore for the first quarter ended June 30, 2026, while revenue from operations rose 16.3 per cent to ₹9,150 crore, driven by broad-based growth across its businesses.

The company’s EBITDA, before forex, other income and exceptional items, increased 20 per cent year-on-year to ₹1,924 crore, with EBITDA margin improving to 21 per cent from 20.4 per cent in the corresponding quarter last year, the Hyderabad base pharma said in a release here.

Profit before tax rose 25.9 per cent to ₹1,517 crore, while earnings per share stood at ₹17.86.

Revenue from the US market grew 8.1 per cent to ₹3,770 crore, while Europe recorded a 25.6 per cent increase to ₹2,937 crore.

Revenue from Growth Markets rose 37.7 per cent to ₹1,063 crore, while ARV business revenue stood at ₹330 crore during the quarter.

The company received final USFDA approvals for 10 products during the quarter and generated free cash flow of USD 98 million.

It also maintained a net cash position of USD 42 million as on June 30, despite completing the USD 247 million acquisition of Lannett and a USD 85 million share buyback.

Commenting on the results, Vice-Chairman and Managing Director K. Nithyananda Reddy said the company had begun FY27 on a strong note with healthy growth across businesses, supported by disciplined execution, operational excellence and a diversified product portfolio.

He said Aurobindo remained well positioned for long-term growth through continued investments and expanding capabilities.

During the quarter, formulations revenue increased 16.5 per cent year-on-year to ₹8,101 crore, while API revenue rose 14.6 per cent to ₹1,049 crore.

The company launched 10 products during the quarter and, as of June 30, had filed 896 ANDAs with the USFDA, receiving 737 final approvals and 33 tentative approvals.

TNT TS